Cellectis Shares and Voting Rights Overview
In the ever-evolving landscape of biotechnology, Cellectis provides crucial updates on its share capital and voting rights. As of the most recent report, the company has made significant strides in transparency and investor relations, which is vital for stakeholders looking to stay informed.
Current Share Capital Status
Cellectis is presently listed on the Euronext Growth market under the ISIN code FR0010425595. This information is critical for investors tracking the company’s market performance.
Total Number of Shares
As of the latest report, Cellectis has a total of 100,325,454 shares in circulation. This figure reflects the company’s growth trajectory and its commitment to increasing shareholder value.
Voting Rights
It’s also noteworthy that the total number of voting rights associated with these shares stands at 89,406,760. This data is essential for understanding the governance and decision-making capabilities within the company.
Contact Information for Stakeholders
Effective communication with investors is pivotal, and Cellectis provides the following avenues for inquiries and further information:
Media Contacts
For media inquiries, Pascalyne Wilson, the Director of Communications, can be reached at +33 (0)7 76 99 14 33 or via email at media@cellectis.com.
Investor Relations
Arthur Stril, the Chief Financial Officer & Chief Business Officer, is available for investor relations questions. Interested parties can reach him via email at investors@cellectis.com.
Understanding the Importance of Share Information
Understanding share capital and voting rights is crucial for potential investors. This information signals not just the financial health of the company but also reflects its operational integrity and strategic direction. Cellectis is committed to providing up-to-date data and fostering transparency to enhance trust among its shareholders.
The Role of Voting Rights in Corporate Governance
Voting rights empower shareholders and give them a voice in key decisions affecting the company. These rights are a reflection of the shareholders’ stake within Cellectis and play a pivotal role in guiding the company's future trajectory. Strengthening corporate governance ensures that shareholder interests align with the actions taken by the management team.
Conclusion
As Cellectis continues to innovate in the biotech sector, maintaining clear channels of communication with its investors is paramount. The latest figures regarding share capital and voting rights showcase the company’s transparency and commitment to shareholder engagement. Understanding these metrics is essential not just for current shareholders but also for potential investors eyeing opportunities within this dynamic field.
Frequently Asked Questions
What is Cellectis' current total number of shares?
The current total number of shares for Cellectis is 100,325,454.
How many voting rights are associated with Cellectis shares?
There are a total of 89,406,760 voting rights associated with Cellectis shares.
Who can I contact for media inquiries related to Cellectis?
For media inquiries, you can reach Pascalyne Wilson at +33 (0)7 76 99 14 33 or via media@cellectis.com.
What is the role of voting rights in Cellectis?
Voting rights allow shareholders to partake in significant decisions regarding the company's governance and strategy.
How can I contact Cellectis for investor relations?
You can contact Arthur Stril at investors@cellectis.com for any investor relations inquiries.
